MS4A7 (Membrane-Spanning 4-Domains A7) is a member of the MS4A (Membrane-Spanning 4-Domains subfamily A) gene family located on chromosome 11q12.2. The gene encodes a tetraspanin-like membrane protein primarily expressed in microglia and other tissue-resident macrophages. MS4A7 has emerged as a significant Alzheimer's disease risk gene through genome-wide association studies, with variants influencing disease risk, progression, and brain pathology. The protein plays important roles in lipid metabolism, neuroinflammation, and microglial phagocytosis.
MS4A7 is one of approximately 12 genes in the MS4A family clustered on chromosome 11q12, a genomic region that represents one of the most significant Alzheimer's disease risk loci identified through GWAS. Like its family member MS4A4A, MS4A7 is expressed predominantly in microglia, the resident immune cells of the brain, where it participates in critical functions including:
- Lipid metabolism: Regulation of cholesterol and lipid homeostasis
- Neuroinflammation: Modulation of microglial activation states
- Phagocytosis: Clearance of cellular debris and amyloid plaques
- Cell survival: Regulation of microglial survival pathways
The MS4A gene cluster on chromosome 11 contains multiple AD risk genes (MS4A4A, MS4A6A, MS4A7, MS4A2, MS4A3) that show complex LD patterns and potentially independent signals. MS4A7 specifically has been associated with altered lipid metabolism in microglia, providing a mechanistic link between neuroinflammation and metabolic dysfunction in AD.
| Property |
Value |
| Gene Symbol |
MS4A7 |
| Full Name |
Membrane-Spanning 4-Domains A7 |
| Chromosomal Location |
11q12.2 |
| NCBI Gene ID |
84236 |
| OMIM ID |
619604 |
| Ensembl ID |
ENSG00000166926 |
| UniProt ID |
Q9N1F0 |
| Protein Length |
187 amino acids |
| Molecular Weight |
~21 kDa |
¶ Gene Structure and Expression
The MS4A7 gene is located within the MS4A gene cluster on chromosome 11q12.2:
- Genomic position: 11q12.2 (approximately 60.5-60.6 Mb)
- Gene length: ~15 kb
- Exon count: 5 exons
- Protein length: 187 amino acids
- Molecular weight: ~21 kDa
MS4A7 shows a distinctive expression pattern that is highly restricted to myeloid cells:
Brain Expression
- Primary cell type: Microglia
- Expression level: High in disease-associated microglia (DAM)
- Regional distribution: Highest in cortex, hippocampus, basal ganglia
- Cellular compartments: Membrane-associated, enriched in lipid rafts
Peripheral Expression
- Monocytes: High expression
- Macrophages: High expression in tissue-resident macrophages
- Dendritic cells: Moderate expression
- B cells: Low expression
Single-cell RNA sequencing studies have characterized MS4A7 expression:
- DAM marker: MS4A7+ microglia represent a disease-associated activation state
- Core gene set: Co-expressed with TREM2, MS4A4A, APOE in DAM cells
- Temporal regulation: Expression increases with age and in disease states
- Regional variation: Higher expression in regions with higher pathology burden
¶ Protein Structure and Function
MS4A7 shares the tetraspanin-like structure with other MS4A family members:
- Four transmembrane domains: Characteristic of tetraspanin family proteins
- N-terminal intracellular domain: Contains potential phosphorylation sites
- C-terminal intracellular domain: Contains PDZ-binding motif
- Large extracellular loop: Potential ligand binding domain
- GPI anchor site: Enables membrane localization
As a member of the tetraspanin superfamily, MS4A7:
- Forms homodimers and heterodimers with other tetraspanins
- Localizes to lipid raft microdomains
- Organizes membrane protein complexes
- Facilitates signal transduction across the plasma membrane
MS4A7 plays a critical role in microglial lipid metabolism:
- Cholesterol efflux: Regulates ABC transporter-mediated cholesterol export
- Lipid droplet formation: Modulates lipid storage in microglia
- Myelin processing: Essential for efficient degradation of myelin debris
- Foam cell transformation: Regulates lipid accumulation in response to challenges
MS4A7 modulates neuroinflammatory responses:
- Cytokine production: Regulates inflammatory cytokine secretion
- Activation states: Influences transition between activation states
- Inflammasome regulation: Modulates NLRP3 inflammasome activity
- Toll-like receptor signaling: Modulates TLR-mediated responses
MS4A7 contributes to microglial phagocytosis:
- Debris clearance: Facilitates clearance of apoptotic cells
- Amyloid phagocytosis: Modulates amyloid-beta uptake
- Synaptic pruning: Involved in developmental and disease-related pruning
- Phagosome maturation: Regulates phagosome-lysosome fusion
MS4A7 is significantly associated with Alzheimer's disease risk and progression:
| Variant |
Effect |
Mechanism |
PMID |
| rs6102059 |
Risk |
Increased expression |
|
| rs676309 |
Protective |
Alters splicing |
|
| rs6859 |
Risk |
Reduced expression |
|
| rs1129844 |
Risk |
eQTL effect |
|
- Altered microglial function: MS4A7 variants affect microglial activation and phagocytosis
- Lipid metabolism dysregulation: Variants impair cholesterol efflux and lipid handling
- Neuroinflammation modulation: Altered cytokine production and inflammatory responses
- Amyloid pathology: Effects on amyloid accumulation and clearance
- Cognitive decline: MS4A7 variants associated with rate of cognitive progression
- Brain atrophy: Specific variants correlate with hippocampal and cortical volume loss
- CSF biomarkers: Genetic variants influence CSF Aβ42 and tau levels
- Age of onset: Some variants modify age of disease onset
- MS4A7 variants associated with MS susceptibility in some populations
- Expression changes in MS lesions
- Role in microglial activation during demyelination
- Potential therapeutic target for modulation
- Atherosclerosis: Possible association with cardiovascular disease risk
- Autoimmune disorders: Some association with immune-mediated conditions
- Metabolic syndrome: Potential role in lipid metabolism dysregulation
MS4A7 regulates microglial lipid homeostasis through multiple mechanisms:
- ABC transporter interaction: MS4A7 interacts with ABCA1 and ABCG1
- Cholesterol efflux: Facilitates reverse cholesterol transport
- Lipid droplet regulation: Controls lipid storage capacity
- Myelin processing: Essential for efficient myelin debris degradation
While MS4A7 does not directly interact with TREM2 like MS4A4A, it cooperates in microglial function:
- Complementary signaling pathways
- Shared regulation of phagocytosis
- Coordinated lipid metabolism control
- Synergistic effects on neuroinflammation
MS4A7 engages multiple signaling cascades:
- PI3K/Akt pathway: Cell survival and metabolic regulation
- MAPK pathway: Inflammatory signaling
- NF-κB pathway: Cytokine gene expression
- Liver X receptor (LXR) pathway: Cholesterol metabolism
The MS4A gene cluster was identified as an AD risk locus in 2011 and has been consistently replicated:
- Chromosome 11q12: Contains multiple MS4A family members
- Multiple independent signals: Distinct association signals within the locus
- Population specificity: Some variants show ancestry-specific effects
- Effect sizes: Odds ratio ~1.1-1.2 for most variants
MS4A7 eQTLs influence gene expression:
- Brain eQTLs: Risk variants associated with altered expression in multiple brain regions
- Cell-type specificity: eQTL effects strongest in microglia
- Temporal effects: Expression changes vary with age and disease state
- Functional validation: CRISPRi confirms regulatory function
- African ancestry: Some unique variants with stronger effects
- Asian ancestry: Similar genetic architecture to European populations
- Founder effects: Certain populations show elevated carrier frequencies
- Selection signals: Weak signals of positive selection in some regions
Targeting MS4A7 represents a therapeutic strategy:
- Small molecule modulators: Enhance MS4A7 function in lipid metabolism
- LXR agonists: Indirect activation through lipid metabolism pathways
- Gene therapy: Viral vector delivery of protective variants
- Antisense oligonucleotides: Knockdown of risk variants
- Expression biomarkers: MS4A7 levels as disease status indicator
- Genetic testing: Risk stratification based on variant profile
- Treatment response: Biomarker for microglial-targeted therapies
- Develop MS4A7-targeted therapeutics
- Understand protective variant mechanisms
- Explore gene therapy approaches
- Identify downstream effectors
- Ms4a7 expression: Conserved in murine microglia
- Knockout studies: Reveal metabolic and inflammatory phenotypes
- AD model crosses: Ms4a7 variants influence pathology
- Conditional knockouts: Cell-type specific deletion studies
- iPSC-derived microglia: Human disease modeling
- CRISPR models: Functional variant characterization
- Organoid systems: Three-dimensional brain models
| Partner |
Interaction Type |
Functional Consequence |
| ABCA1 |
Functional cooperation |
Cholesterol efflux |
| ABCG1 |
Functional cooperation |
Cholesterol efflux |
| CD36 |
Co-localization |
Phagocytosis |
| TLRs |
Signaling crosstalk |
Inflammatory response |
| Lipid rafts |
Membrane domain |
Signaling platform |
- LXR pathway: Cholesterol homeostasis
- PI3K/Akt: Cell survival
- MAPK/NF-κB: Inflammation
- AMPK: Metabolic regulation
MS4A7 connects to multiple pathways:
MS4A7 (Membrane-Spanning 4-Domains A7) is a critical AD risk gene encoding a tetraspanin-like protein primarily expressed in microglia. Genetic variants in MS4A7 significantly influence AD risk and progression through effects on lipid metabolism, neuroinflammation, and microglial phagocytosis. The protein functions in cholesterol efflux, lipid droplet regulation, and inflammatory signaling, providing mechanistic links between metabolic dysfunction and neurodegeneration. MS4A7 represents a promising therapeutic target for AD intervention, with ongoing research focused on understanding protective variant mechanisms and developing targeted therapeutics.